6-methyl-1H-pyrido[2,3-b][1,4]oxazin-2-one | 1198153-91-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-methyl-1H-pyrido[2,3-b][1,4]oxazin-2-one
• 英文别名: 6-methyl-1H,2H,3H-pyrido[2,3-b][1,4]oxazin-2-one
• CAS: 1198153-91-1
• 化学式: C₈H₈N₂O₂
• mdl: MFCD23701960
• 分子量: 164.164
• InChiKey: OBKUXCCMPCVLGB-UHFFFAOYSA-N

物化性质

• 熔点：
  >195?C (dec.)
• 溶解度：
  乙腈（微溶）、氯仿（微溶）、DMSO（微溶）、甲醇（微溶）

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  51.2
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
  申请人：BlinkBio, Inc.

  公开号：US20170202970A1

  公开（公告）日：2017-07-20

  Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.

  本文描述了基于硅的共轭物，能够将一个或多个有效载荷基团传递到靶细胞或组织。考虑到的共轭物可能包括一个硅-杂原子核心，一个或多个可选的催化基团，一个定位基团，允许共轭物在靶细胞或组织内积累，一个或多个有效载荷基团（例如，治疗剂或成像剂），以及与硅-杂原子核心共价结合的两个或更多个不干扰基团。
• [EN] OGA INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'OGA
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2019243527A1

  公开（公告）日：2019-12-26

  The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations.

  本发明涉及O-GlcNAc水解酶（OGA）抑制剂。该发明还涉及包含这类化合物的药物组合物，制备这类化合物和组合物的方法，以及利用这类化合物和组合物预防和治疗抑制OGA有益的疾病的用途，例如tau病变，特别是阿尔茨海默病或进行性核上性麻痹症；以及伴有tau病理的神经退行性疾病，特别是由C90RF72突变引起的肌萎缩侧索硬化或额颞叶痴呆症。
• HETEROCYCLIC DERIVATIVES
  申请人：Ahn Sung Oh

  公开号：US20110028467A1

  公开（公告）日：2011-02-03

  The present invention relates to heterocyclic derivatives, and more particularly, to novel heterocyclic derivatives useful for the preparation of medicaments for treating diseases related to uric acid.

  本发明涉及杂环衍生物，更具体地，涉及用于制备治疗与尿酸相关疾病的药物的新颖杂环衍生物。
• TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
  申请人：Shanghai Jemincare Pharmaceuticals Co., Ltd.

  公开号：EP3998263A1

  公开（公告）日：2022-05-18

  A compound represented by formula (I), an optical isomer thereof and a pharmaceutically acceptable salt thereof, as well as an application of said compound as an FXIa inhibitor.

  化合物(I)及其光学异构体和药学上可接受的盐，以及该化合物作为FXIa抑制剂的应用。
• Syk inhibitors
  申请人：Gilead Sciences, Inc.

  公开号：US10005774B2

  公开（公告）日：2018-06-26

  The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein X1, X2, X3, R2, R3, R4, R5, and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

  本公开涉及作为 Syk 抑制剂的化合物及其在治疗各种疾病（包括癌症和炎症）中的用途。在特定的实施方案中，化合物的结构如式 I 所示： 其中 X1、X2、X3、R2、R3、R4、R5 和 Y 如本文所述。本公开进一步提供了包括式 I 的化合物或其药学上可接受的盐的药物组合物，以及使用这些化合物和组合物治疗由 Syk 介导的病症的方法。